Comprehensive analysis of the expression, prognosis and biological significance of FSCN family in clear cell renal cell carcinoma

Lin,Yongping; Chen,Ru; Jiang,Ming; Hu,Bing; Zheng,Ping; Chen,Guoxian

doi:10.3892/ol.2023.13965

Comprehensive analysis of the expression, prognosis and biological significance of FSCN family in clear cell renal cell carcinoma

Authors:
- Yongping Lin
- Ru Chen
- Ming Jiang
- Bing Hu
- Ping Zheng
- Guoxian Chen
View Affiliations

Affiliations: Department of Urology, The First Hospital of Putian City, Putian, Fujian 351100, P.R. China, Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Urology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Urology, Shangrao Municipal Hospital, Shangrao, Jiangxi 334000, P.R. China
Published online on: July 20, 2023 https://doi.org/10.3892/ol.2023.13965
Article Number: 379
Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fascin (FSCN) is an actin‑binding protein that serves a critical role in cell migration and invasion, contributing to tumor metastasis. However, there is little known about the function of FSCN family in kidney renal clear cell carcinoma (KIRC). The present study used the UALCAN, gene expression profiling interactive analysis, The Cancer Genome Atlas, cBioPortal, STRING and The Tumor Immune Estimation Resource databases to investigate the transcription level, genetic alteration and biological function of FSCNs in KIRC and their association with the prognosis value and immune cell infiltration in patients with KIRC. Results showed that the expression of FSCN1 and FSCN3 was markedly upregulated in patients with KIRC, while the expression of FSCN2 showed an opposite trend, which was the same as the experiments. Furthermore, the expression levels of FSCNs were associated with pathological stage, molecular subtypes and tumor grade. The expression levels of FSCNs were statistically correlated with the immune cell infiltration in KIRC. Higher expression levels of FSCN1 and FSCN3 were associated with worse overall survival (OS) and progression‑free interval of patients bearing KIRC. Univariate and multivariate analysis demonstrated that FSCN2 was an independent risk factor for OS time in KIRC. Furthermore, mutations in FSCNs were significantly associated with poor OS and progression‑free survival in patients with KIRC. The FSCNs were involved in pathways including focal adhesion, endocytosis, hypertrophic cardiomyopathy, regulation of actin cytoskeleton. The results indicated that FSCN2 might serve as an independent prognostic factor for OS of KIRC and that FSCN1 and FSCN3 can be used as favorable biomarkers for predicting clinical outcomes in KIRC.

View Figures

View References

1	Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, et al: European association of urology guidelines on renal cell carcinoma: The 2019 update. Eur Urol. 75:799–810. 2019. View Article : Google Scholar : PubMed/NCBI
2	Cairns P: Renal cell carcinoma. Cancer Biomark. 9:461–473. 2010. View Article : Google Scholar : PubMed/NCBI
3	Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grunwald V, Gillessen S and Horwich A; ESMO Guidelines Committee, : Electronic address: simpleclinicalguidelines@esmo.org. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 30:706–720. 2019. View Article : Google Scholar : PubMed/NCBI
4	Capitanio U and Montorsi F: Renal cancer. Lancet. 387:894–906. 2016. View Article : Google Scholar : PubMed/NCBI
5	Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, et al: Updated European association of urology guidelines regarding adjuvant therapy for renal cell carcinoma. Eur Urol. 71:719–722. 2017. View Article : Google Scholar : PubMed/NCBI
6	Bhalla S, Chaudhary K, Kumar R, Sehgal M, Kaur H, Sharma S and Raghava GP: Gene expression-based biomarkers for discriminating early and late stage of clear cell renal cancer. Sci Rep. 7:449972017. View Article : Google Scholar : PubMed/NCBI
7	Li A, Dawson JC, Forero-Vargas M, Spence HJ, Yu X, König I, Anderson K and Machesky LM: The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol. 20:339–345. 2010. View Article : Google Scholar : PubMed/NCBI
8	Adams JC: Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol. 16:590–596. 2004. View Article : Google Scholar : PubMed/NCBI
9	Schoumacher M, Goldman RD, Louvard D and Vignjevic DM: Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J Cell Biol. 189:541–556. 2010. View Article : Google Scholar : PubMed/NCBI
10	Kureishy N, Sapountzi V, Prag S, Anilkumar N and Adams JC: Fascins, and their roles in cell structure and function. Bioessays. 24:350–361. 2002. View Article : Google Scholar : PubMed/NCBI
11	Yamashiro S, Yamakita Y, Ono S and Matsumura F: Fascin, an actin-bundling protein, induces membrane protrusions and increases cell motility of epithelial cells. Mol Biol Cell. 9:993–1006. 1998. View Article : Google Scholar : PubMed/NCBI
12	Hayashi Y, Osanai M and Lee GH: Fascin-1 expression correlates with repression of E-cadherin expression in hepatocellular carcinoma cells and augments their invasiveness in combination with matrix metalloproteinases. Cancer Sci. 102:1228–1235. 2011. View Article : Google Scholar : PubMed/NCBI
13	Vignjevic D, Schoumacher M, Gavert N, Janssen KP, Jih G, Laé M, Louvard D, Ben-Ze'ev A and Robine S: Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res. 67:6844–6853. 2007. View Article : Google Scholar : PubMed/NCBI
14	Darnel AD, Behmoaram E, Vollmer RT, Corcos J, Bijian K, Sircar K, Su J, Jiao J, Alaoui-Jamali MA and Bismar TA: Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res. 15:1376–1383. 2009. View Article : Google Scholar : PubMed/NCBI
15	Shin JB, Longo-Guess CM, Gagnon LH, Saylor KW, Dumont RA, Spinelli KJ, Pagana JM, Wilmarth PA, David LL, Gillespie PG and Johnson KR: The R109H variant of fascin-2, a developmentally regulated actin crosslinker in hair-cell stereocilia, underlies early-onset hearing loss of DBA/2J mice. J Neurosci. 30:9683–9694. 2010. View Article : Google Scholar : PubMed/NCBI
16	Liu X, Zhao M, Xie Y, Li P, Wang O, Zhou B, Yang L, Nie Y, Cheng L, Song X, et al: Null mutation of the Fascin2 gene by TALEN leading to progressive hearing loss and retinal degeneration in C57BL/6J mice. G3 (Bethesda). 8:3221–3230. 2018. View Article : Google Scholar : PubMed/NCBI
17	Tubb B, Mulholland DJ, Vogl W, Lan ZJ, Niederberger C, Cooney A and Bryan J: Testis fascin (FSCN3): A novel paralog of the actin-bundling protein fascin expressed specifically in the elongate spermatid head. Exp Cell Res. 275:92–109. 2002. View Article : Google Scholar : PubMed/NCBI
18	Lin J, Jiang M, Chen R, Zheng P and Chen G: Comprehensive analysis of the expression, prognostic value and biological importance of OVO-like proteins in clear cell renal cell carcinoma. Oncol Lett. 25:1792023. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45((W1)): W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
21	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
22	Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R and Getz G: GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12:R412011. View Article : Google Scholar : PubMed/NCBI
23	Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al: STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47(D1): D607–D613. 2019. View Article : Google Scholar : PubMed/NCBI
24	Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al: Comprehensive analyses of tumor immunity: Implications for cancer immunotherapy. Genome Biol. 17:1742016. View Article : Google Scholar : PubMed/NCBI
25	Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, et al: An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI
26	Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
27	Kim SJ, Choi IJ, Cheong TC, Lee SJ, Lotan R, Park SH and Chun KH: Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology. 138:1035–1045.e1-e2. 2010. View Article : Google Scholar : PubMed/NCBI
28	Onodera M, Zen Y, Harada K, Sato Y, Ikeda H, Itatsu K, Sato H, Ohta T, Asaka M and Nakanuma Y: Fascin is involved in tumor necrosis factor-alpha-dependent production of MMP9 in cholangiocarcinoma. Lab Invest. 89:1261–1274. 2009. View Article : Google Scholar : PubMed/NCBI
29	Vignjevic D, Kojima S, Aratyn Y, Danciu O, Svitkina T and Borisy GG: Role of fascin in filopodial protrusion. J Cell Biol. 174:863–875. 2006. View Article : Google Scholar : PubMed/NCBI
30	Yoder BJ, Tso E, Skacel M, Pettay J, Tarr S, Budd T, Tubbs RR, Adams JC and Hicks DG: The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res. 11:186–192. 2005. View Article : Google Scholar : PubMed/NCBI
31	Wu D, Chen L, Liao W, Ding Y, Zhang Q, Li Z and Liu L: Fascin1 expression predicts poor prognosis in patients with nasopharyngeal carcinoma and correlates with tumor invasion. Ann Oncol. 21:589–596. 2010. View Article : Google Scholar : PubMed/NCBI
32	Hashimoto Y, Kim DJ and Adams JC: The roles of fascins in health and disease. J Pathol. 224:289–300. 2011. View Article : Google Scholar : PubMed/NCBI
33	Machesky LM and Li A: Fascin: Invasive filopodia promoting metastasis. Commun Integr Biol. 3:263–270. 2010. View Article : Google Scholar : PubMed/NCBI
34	Tan VY, Lewis SJ, Adams JC and Martin RM: Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: A systematic review and meta-analysis. BMC Med. 11:522013. View Article : Google Scholar : PubMed/NCBI
35	Zhang X, Cho IH, Park JH, Lee MK and Hwang YS: Fascin is involved in cancer cell invasion and is regulated by stromal factors. Oncol Rep. 41:465–474. 2019.PubMed/NCBI
36	Han S, Huang J, Liu B, Xing B, Bordeleau F, Reinhart-King CA, Li W, Zhang JJ and Huang XY: Improving fascin inhibitors to block tumor cell migration and metastasis. Mol Oncol. 10:966–980. 2016. View Article : Google Scholar : PubMed/NCBI
37	McGuire S, Kara B, Hart PC, Montag A, Wroblewski K, Fazal S, Huang XY, Lengyel E and Kenny HA: Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis. Gynecol Oncol. 153:405–415. 2019. View Article : Google Scholar : PubMed/NCBI
38	Park KS, Yoon SY, Park SH and Hwang JH: Anti-migration and anti-invasion effects of curcumin via suppression of fascin expression in glioblastoma cells. Brain Tumor Res Treat. 7:16–24. 2019. View Article : Google Scholar : PubMed/NCBI
39	Zhao D, Zhang T, Hou XM and Ling XL: Knockdown of fascin-1 expression suppresses cell migration and invasion of non-small cell lung cancer by regulating the MAPK pathway. Biochem Biophys Res Commun. 497:694–699. 2018. View Article : Google Scholar : PubMed/NCBI
40	Wang C, Wang J, Chen Z, Gao Y and He J: Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: A systematic review. Chin J Cancer. 36:652017. View Article : Google Scholar : PubMed/NCBI
41	Wada Y, Abe T, Takeshita T, Sato H, Yanashima K and Tamai M: Mutation of human retinal fascin gene (FSCN2) causes autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 42:2395–2400. 2001.PubMed/NCBI